Nebion becomes a subsidiary of New-York based Immunai

Founded in 2010, Nebion specialises in curating public gene expression datasets and developing intuitive discovery tools. Its data mining engine is deeply curated with the highest quality transcriptomic data of microarrays and RNA-sequence, bulk tissues and single-cell, private and public data. The platform help researchers and clinicians in the pharmaceutical and biotech industry learn from the transcriptomic data to understand and apply machine learning to biology and identify targets and biomarkers for exciting discoveries in academia and industry. Nebion’s single-cell data integration approaches represent a unique asset for high-resolution target identification and in-silico validation of candidate genes.

After 13 years, Nebion embarks on a new journey as a subsidiary of Immunai, a New York and Tel Aviv-based biotech company that uses single-cell genomics and machine learning to discover and develop novel therapeutics that reprogram the immune system. With the acquisition, Immunai seeks to incorporate Nebion’s deeply curated public datasets to expand AMICATM, Immunai’s Annotated Multiomic Immunological Cell Atlas, already the largest such database in the world.

This data will improve Immunai’s machine learning models, enabling the platform to find drug targets from aggregated public data sets and providing validation data for targets found through other methods. Furthermore, Immunai’s partners will have access to more robust and granular insights, improving their drug discovery and development process quality.

Nebion will continue to operate under that name. The integration of both companies will take place over the following months. In their statement, Nebion said it would “work closely with its clients, partners, and employees to make the integration process as smooth as possible. All customers will continue to receive the same high-quality service and commitment, which they have come to expect.”

Renowned executives join Nebion and Immunai
In addition, Immunai has brought on several key executives, including Moderna co-founder Robert Langer as Board Member, world-renowned immunologist Jacques Banchereau as Chief Science Officer, and Chief Business Officer Mark Jacobstein. The company has raised more than $90M in capital to date to build its drug discovery platform.

(Press release/RAN)